Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

NCT06630286 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

609

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1-infection

Interventions

DRUG: ISL/LEN
DRUG: B/F/TAF
DRUG: PTM B/F/TAF
DRUG: PTM ISL/LEN

Sponsor

Gilead Sciences

Collaborators

[object Object]